You are here:

boceprevir (Victrelis) Naive Patients

Advice

following a full submission

boceprevir (Victrelis®) is accepted  for use within NHS Scotland.

Indication under review: Treatment of chronic hepatitis C (HCV) genotype 1 infection, in combination with peginterferon and ribavirin, in adult patients with compensated liver disease who are previously untreated.

In the pivotal, phase III randomised study, addition of boceprevir to current standard therapy in patients with HCV who were previously untreated increased the proportion of patients with HCV who achieved a sustained virologic response.
 

Drug Details

Drug Name: boceprevir (Victrelis) Naive Patients
SMC Drug ID: 723/11
Manufacturer: Merck Sharp and Dohme Ltd
Indication: Treatment of chronic hepatitis C (HCV) genotype 1 infection, in combination with peginterferon and ribavirin, in adult patients with compensated liver disease who are previously untreated.
BNF Category:
Sub Category: 5.3 Antiviral Drugs
Submission Type: Full submission
Status: Accepted
Date Advice Published: 10 October 2011

Back